Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ONCT Oncternal Therapeutics, Inc. daily Stock Chart
ONCT [NASD]
Oncternal Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.29 Insider Own18.40% Shs Outstand15.58M Perf Week-17.46%
Market Cap75.87M Forward P/E- EPS next Y-1.11 Insider Trans- Shs Float0.13M Perf Month-23.91%
Income-30.70M PEG- EPS next Q- Inst Own24.50% Short Float- Perf Quarter-38.43%
Sales2.52M P/S30.10 EPS this Y5.70% Inst Trans-0.10% Short Ratio- Perf Half Y-28.09%
Book/sh0.87 P/B5.60 EPS next Y-14.40% ROA-86.40% Target Price1.50 Perf Year-95.32%
Cash/sh1.36 P/C3.58 EPS next 5Y0.00% ROE-104.20% 52W Range4.61 - 179.20 Perf YTD-10.81%
Dividend- P/FCF- EPS past 5Y24.40% ROI- 52W High-97.28% Beta6.09
Dividend %- Quick Ratio12.40 Sales past 5Y- Gross Margin- 52W Low5.64% ATR0.68
Employees21 Current Ratio12.40 Sales Q/Q- Oper. Margin- RSI (14)34.25 Volatility9.72% 10.42%
OptionableYes Debt/Eq0.00 EPS Q/Q60.90% Profit Margin- Rel Volume0.18 Prev Close4.86
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume40.65K Price4.87
Recom3.00 SMA20-23.62% SMA50-30.43% SMA200-41.20% Volume7,208 Change0.31%
Jun-10-19 08:00AM  Oncternal Therapeutics Completes Reverse Merger with GTx, Inc. GlobeNewswire -16.31%
Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.
open in yahoo | open in reuters | open in google